Log in

NASDAQ:AMRNAmarin Stock Price, Forecast & News

$6.92
-0.11 (-1.56 %)
(As of 07/3/2020 01:56 PM ET)
Add
Compare
Today's Range
$6.89
Now: $6.92
$7.11
50-Day Range
$6.59
MA: $7.00
$7.73
52-Week Range
$3.95
Now: $6.92
$26.12
Volume4.01 million shs
Average Volume6.49 million shs
Market Capitalization$2.67 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.72
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
Read More
Amarin logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$429.76 million
Book Value$1.63 per share

Profitability

Net Income$-22,650,000.00

Miscellaneous

EmployeesN/A
Market Cap$2.67 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

Amarin (NASDAQ:AMRN) Frequently Asked Questions

How has Amarin's stock been impacted by COVID-19 (Coronavirus)?

Amarin's stock was trading at $12.56 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AMRN shares have decreased by 44.9% and is now trading at $6.92. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amarin?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amarin.

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Amarin.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) released its quarterly earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. The biopharmaceutical company earned $155 million during the quarter, compared to analysts' expectations of $150.06 million. Amarin had a negative net margin of 3.67% and a negative return on equity of 4.05%. The business's revenue was up 111.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.05) earnings per share. View Amarin's earnings history.

What price target have analysts set for AMRN?

13 analysts have issued 12 month price targets for Amarin's shares. Their forecasts range from $4.00 to $51.00. On average, they anticipate Amarin's share price to reach $17.23 in the next year. This suggests a possible upside of 149.0% from the stock's current price. View analysts' price targets for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. According to Zacks Investment Research, "Amarin reported encouraging fourth-quarter results, wherein both earnings and sales beat estimates. Amarin’s sole marketed drug Vascepa has been on a strong growth trajectory for the last four years. The drug’s recent label expansion for cardiovascular indication looks promising. The growth trend for Vascepa is expected to continue in 2020. The company is expanding its sales force and start promotional programs to create awareness for Vascepa’s expanded label. These initiatives are likely to drive sales higher. The company is looking to get approval for the drug in additional countries. However, Amarin is over-dependent on Vascepa for its growth. Any setback to its commercialization plans will have an unfavorable impact. Competition is also rising in the targeted market. Shares have underperformed the industry in the past year." (3/5/2020)
  • 2. HC Wainwright analysts commented, "Our PT of $51 is based on equally weighted average of: (a) $47.99/share, as a 25x multiple of taxed and diluted FY29 GAAP EPS of $5.45 discounted back to and (b) an NPV of $53.14/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) Vascepa commercial ramp-up and/or peak sales not meeting our projections; and (2) further competitive disruption of the omega-3 market by branded drugs or generics and/ or OTC supplements beyond our model." (8/1/2019)

Has Amarin been receiving favorable news coverage?

Media coverage about AMRN stock has been trending somewhat positive on Friday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amarin earned a daily sentiment score of 1.6 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Amarin.

Are investors shorting Amarin?

Amarin saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 34,120,000 shares, a decline of 5.7% from the May 31st total of 36,180,000 shares. Based on an average trading volume of 15,450,000 shares, the days-to-cover ratio is currently 2.2 days. Approximately 9.7% of the company's shares are sold short. View Amarin's Current Options Chain.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Canopy Growth (CGC), Square (SQ), Alibaba Group (BABA), Gilead Sciences (GILD), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

Who are Amarin's key executives?

Amarin's management team includes the following people:
  • John F. Thero, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Craig B. Granowitz, Chief Medical Officer

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $6.92.

How big of a company is Amarin?

Amarin has a market capitalization of $2.67 billion and generates $429.76 million in revenue each year. The biopharmaceutical company earns $-22,650,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

What is Amarin's official website?

The official website for Amarin is www.amarincorp.com.

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.